CS131891A3 - Vaccine - Google Patents

Vaccine Download PDF

Info

Publication number: CS131891A3
Authority: CS; Czechoslovakia
Prior art keywords: group; composition; amino acid; polypeptide; composition according
Prior art date: 1990-05-07

Application number

CS911318A

Other languages

Czech (cs)

English (en)

Inventor

Christopher L Penny

Original Assignee

North American Vaccine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-05-07

Filing date

1991-05-06

Publication date

1992-02-19

1991-05-06 Application filed by North American Vaccine filed Critical North American Vaccine

1992-02-19 Publication of CS131891A3 publication Critical patent/CS131891A3/cs

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 31
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 83
229920001184 polypeptide Polymers 0.000 claims abstract description 73
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 72
239000000203 mixture Substances 0.000 claims abstract description 54
230000002163 immunogen Effects 0.000 claims abstract description 40
239000002671 adjuvant Substances 0.000 claims description 35
239000000546 pharmaceutical excipient Substances 0.000 claims description 30
238000000034 method Methods 0.000 claims description 26
235000001014 amino acid Nutrition 0.000 claims description 23
108091007433 antigens Proteins 0.000 claims description 23
239000000427 antigen Substances 0.000 claims description 22
102000036639 antigens Human genes 0.000 claims description 22
150000001413 amino acids Chemical class 0.000 claims description 21
125000000217 alkyl group Chemical group 0.000 claims description 16
125000003275 alpha amino acid group Chemical group 0.000 claims description 16
208000006454 hepatitis Diseases 0.000 claims description 12
241000700605 Viruses Species 0.000 claims description 11
239000003795 chemical substances by application Substances 0.000 claims description 11
231100000283 hepatitis Toxicity 0.000 claims description 11
GHAXTSRJNHYMFC-SANMLTNESA-N (2s)-3-(4-hydroxyphenyl)-2-(octadecylamino)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCCN[C@H](C(O)=O)CC1=CC=C(O)C=C1 GHAXTSRJNHYMFC-SANMLTNESA-N 0.000 claims description 10
241000725303 Human immunodeficiency virus Species 0.000 claims description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
125000000539 amino acid group Chemical group 0.000 claims description 7
150000002148 esters Chemical class 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 7
108090000623 proteins and genes Proteins 0.000 claims description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
239000000463 material Substances 0.000 claims description 6
229910052760 oxygen Inorganic materials 0.000 claims description 6
108010016626 Dipeptides Proteins 0.000 claims description 5
208000000474 Poliomyelitis Diseases 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
208000002672 hepatitis B Diseases 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
206010025280 Lymphocytosis Diseases 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims description 4
230000028993 immune response Effects 0.000 claims description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
125000004430 oxygen atom Chemical group O* 0.000 claims description 4
230000001717 pathogenic effect Effects 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
229960000814 tetanus toxoid Drugs 0.000 claims description 4
125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 3
241000283690 Bos taurus Species 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
206010043376 Tetanus Diseases 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 3
125000006290 2-hydroxybenzyl group Chemical group [H]OC1=C(C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 claims description 2
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
208000030507 AIDS Diseases 0.000 claims description 2
108010077805 Bacterial Proteins Proteins 0.000 claims description 2
241000725619 Dengue virus Species 0.000 claims description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
241000709661 Enterovirus Species 0.000 claims description 2
208000007212 Foot-and-Mouth Disease Diseases 0.000 claims description 2
241000710198 Foot-and-mouth disease virus Species 0.000 claims description 2
XBGGUPMXALFZOT-VIFPVBQESA-N Gly-Tyr Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-VIFPVBQESA-N 0.000 claims description 2
108010008488 Glycylglycine Proteins 0.000 claims description 2
208000009889 Herpes Simplex Diseases 0.000 claims description 2
201000005505 Measles Diseases 0.000 claims description 2
208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 2
241000702670 Rotavirus Species 0.000 claims description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 2
HPYDSVWYXXKHRD-VIFPVBQESA-N Tyr-Gly Chemical compound [O-]C(=O)CNC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 HPYDSVWYXXKHRD-VIFPVBQESA-N 0.000 claims description 2
HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 claims description 2
235000011054 acetic acid Nutrition 0.000 claims description 2
235000008206 alpha-amino acids Nutrition 0.000 claims description 2
229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims description 2
229960003983 diphtheria toxoid Drugs 0.000 claims description 2
206010014599 encephalitis Diseases 0.000 claims description 2
238000009472 formulation Methods 0.000 claims description 2
XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 claims description 2
229940043257 glycylglycine Drugs 0.000 claims description 2
208000005252 hepatitis A Diseases 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
239000004310 lactic acid Substances 0.000 claims description 2
235000014655 lactic acid Nutrition 0.000 claims description 2
201000004792 malaria Diseases 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
230000001737 promoting effect Effects 0.000 claims description 2
239000011975 tartaric acid Substances 0.000 claims description 2
235000002906 tartaric acid Nutrition 0.000 claims description 2
108010017949 tyrosyl-glycyl-glycine Proteins 0.000 claims description 2
241000701161 unidentified adenovirus Species 0.000 claims description 2
241000712461 unidentified influenza virus Species 0.000 claims description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
241000712891 Arenavirus Species 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
241000282326 Felis catus Species 0.000 claims 1
208000005176 Hepatitis C Diseases 0.000 claims 1
GLUBLISJVJFHQS-VIFPVBQESA-N Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 GLUBLISJVJFHQS-VIFPVBQESA-N 0.000 claims 1
241000725643 Respiratory syncytial virus Species 0.000 claims 1
241000700584 Simplexvirus Species 0.000 claims 1
150000001371 alpha-amino acids Chemical class 0.000 claims 1
125000003118 aryl group Chemical group 0.000 claims 1
SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 claims 1
230000001413 cellular effect Effects 0.000 claims 1
108010077435 glycyl-phenylalanyl-glycine Proteins 0.000 claims 1
108010087823 glycyltyrosine Proteins 0.000 claims 1
125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
208000032839 leukemia Diseases 0.000 claims 1
235000015250 liver sausages Nutrition 0.000 claims 1
229940066827 pertussis vaccine Drugs 0.000 claims 1
XYSQXZCMOLNHOI-UHFFFAOYSA-N s-[2-[[4-(acetylsulfamoyl)phenyl]carbamoyl]phenyl] 5-pyridin-1-ium-1-ylpentanethioate;bromide Chemical compound [Br-].C1=CC(S(=O)(=O)NC(=O)C)=CC=C1NC(=O)C1=CC=CC=C1SC(=O)CCCC[N+]1=CC=CC=C1 XYSQXZCMOLNHOI-UHFFFAOYSA-N 0.000 claims 1
239000003053 toxin Substances 0.000 claims 1
231100000765 toxin Toxicity 0.000 claims 1
JREYOWJEWZVAOR-UHFFFAOYSA-N triazanium;[3-methylbut-3-enoxy(oxido)phosphoryl] phosphate Chemical compound [NH4+].[NH4+].[NH4+].CC(=C)CCOP([O-])(=O)OP([O-])([O-])=O JREYOWJEWZVAOR-UHFFFAOYSA-N 0.000 claims 1
-1 alkyl compound Chemical class 0.000 abstract description 17
230000001571 immunoadjuvant effect Effects 0.000 abstract description 13
239000000568 immunological adjuvant Substances 0.000 abstract description 13
210000000987 immune system Anatomy 0.000 abstract description 4
230000003213 activating effect Effects 0.000 abstract 1
230000036039 immunity Effects 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 description 14
230000003000 nontoxic effect Effects 0.000 description 14
241000699670 Mus sp. Species 0.000 description 10
230000000694 effects Effects 0.000 description 10
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 9
229910052782 aluminium Inorganic materials 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 7
239000000126 substance Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
230000005875 antibody response Effects 0.000 description 6
241000282412 Homo Species 0.000 description 5
241000282520 Papio Species 0.000 description 5
125000005907 alkyl ester group Chemical group 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
239000000047 product Substances 0.000 description 5
238000003127 radioimmunoassay Methods 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000010668 complexation reaction Methods 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000002649 immunization Methods 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
230000003308 immunostimulating effect Effects 0.000 description 4
238000010647 peptide synthesis reaction Methods 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
VHUVBWVDIFVVBI-SNYZSRNZSA-N (2s)-3-(4-hydroxyphenyl)-2-(octadecylamino)propanoic acid;hydrochloride Chemical group Cl.CCCCCCCCCCCCCCCCCCN[C@H](C(O)=O)CC1=CC=C(O)C=C1 VHUVBWVDIFVVBI-SNYZSRNZSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 3
159000000007 calcium salts Chemical class 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
238000001784 detoxification Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
206010011224 Cough Diseases 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
229940037003 alum Drugs 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
229940030156 cell vaccine Drugs 0.000 description 2
230000008859 change Effects 0.000 description 2
229940028617 conventional vaccine Drugs 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229960002449 glycine Drugs 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
150000002431 hydrogen Chemical class 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000006104 solid solution Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000004448 titration Methods 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 1
DLZKEQQWXODGGZ-KCJUWKMLSA-N 2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KCJUWKMLSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000714266 Bovine leukemia virus Species 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
206010019773 Hepatitis G Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102100034349 Integrase Human genes 0.000 description 1
241001026509 Kata Species 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
206010023927 Lassa fever Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
101150010882 S gene Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
229920002359 Tetronic® Polymers 0.000 description 1
206010045240 Type I hypersensitivity Diseases 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000013566 allergen Substances 0.000 description 1
150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
150000004645 aluminates Chemical class 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
229910052785 arsenic Inorganic materials 0.000 description 1
RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
239000012620 biological material Substances 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
231100000313 clinical toxicology Toxicity 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000000586 desensitisation Methods 0.000 description 1
FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
238000001914 filtration Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229960001269 glycine hydrochloride Drugs 0.000 description 1
108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
229960002520 hepatitis vaccine Drugs 0.000 description 1
230000007236 host immunity Effects 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
229940044173 iodine-125 Drugs 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
UHGIMQLJWRAPLT-UHFFFAOYSA-N octadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCCCOP(O)(O)=O UHGIMQLJWRAPLT-UHFFFAOYSA-N 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
239000003566 sealing material Substances 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
230000008280 toxic mechanism Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
108010005834 tyrosyl-alanyl-glycine Proteins 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
229940125575 vaccine candidate Drugs 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Mycology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Immunology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Oscillators With Electromechanical Resonators (AREA)
Diaphragms For Electromechanical Transducers (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)

CS911318A 1990-05-07 1991-05-06 Vaccine CS131891A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US51846090A	1990-05-07	1990-05-07

Publications (1)

Publication Number	Publication Date
CS131891A3 true CS131891A3 (en)	1992-02-19

Family

ID=24064028

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS911318A CS131891A3 (en)	1990-05-07	1991-05-06	Vaccine

Country Status (22)

Country	Link
EP (1)	EP0597838B1 (de)
JP (1)	JPH05506234A (de)
CN (1)	CN1056816A (de)
AT (1)	ATE173936T1 (de)
AU (1)	AU7777991A (de)
CA (1)	CA2082425A1 (de)
CS (1)	CS131891A3 (de)
DE (1)	DE69130576T2 (de)
DK (1)	DK0597838T3 (de)
ES (1)	ES2124701T3 (de)
FI (1)	FI925032A7 (de)
HR (1)	HRP930658A2 (de)
HU (1)	HUT65493A (de)
IE (1)	IE911527A1 (de)
IL (1)	IL97985A0 (de)
MX (1)	MX172210B (de)
NO (1)	NO924271L (de)
NZ (1)	NZ238042A (de)
TW (1)	TW221676B (de)
WO (1)	WO1991016926A1 (de)
YU (1)	YU79691A (de)
ZA (1)	ZA913214B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA22842A1 (fr) *	1992-03-27	1993-10-01	Smithkline Beecham Biolog	Procede de preparation de compositions de vaccin.
US6620414B2 (en)	1992-03-27	2003-09-16	Smithkline Beecham Biologicals (S.A.)	Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
AU3541495A (en) *	1994-09-01	1996-03-22	Wisconsin Alumni Research Foundation	Therapeutic remodeling in aids
FR2726471B1 (fr)	1994-11-07	1997-01-31	Pf Medicament	Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
US6027731A (en) *	1998-11-17	2000-02-22	Wisconsin Alumni Research Foundation	Pertussis toxin induced lymphocytosis
AU2221600A (en)	1998-12-31	2000-07-31	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
CA2358915C (en)	1998-12-31	2010-06-01	Chiron Corporation	Modified hiv env polypeptides
WO2000039304A2 (en)	1998-12-31	2000-07-06	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP2412242A3 (de)	2001-07-05	2012-06-13	Novartis Vaccines and Diagnostics, Inc.	Polypeptide vom HIV-Typ C codierende Polynucleotide, Polypeptide und deren Verwendung
US20030170614A1 (en)	2001-08-31	2003-09-11	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
EP1551495A4 (de)	2002-10-10	2010-06-02	Yeda Res & Dev	Basische ester von fettalkoholen und ihre verwendung als entzündungshemmende oder immunmodulatorische mittel

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1138773A (en) *	1979-04-18	1983-01-04	Connaught Laboratories Limited	Synthetic adjuvants for stimulation of antigenic responses
US4639371A (en) *	1984-10-02	1987-01-27	New York Blood Center, Inc.	Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom
GB8807860D0 (en) *	1988-04-05	1988-05-05	Connaught Lab	Pertussis vaccine
NZ230424A (en) *	1988-08-25	1992-05-26	Liposome Co Inc	Liposomal composition comprising an externally disposed antigen

1991
- 1991-04-28 IL IL97985A patent/IL97985A0/xx unknown
- 1991-04-29 ZA ZA913214A patent/ZA913214B/xx unknown
- 1991-05-01 FI FI925032A patent/FI925032A7/fi not_active Application Discontinuation
- 1991-05-01 HU HU9203480A patent/HUT65493A/hu unknown
- 1991-05-01 AU AU77779/91A patent/AU7777991A/en not_active Abandoned
- 1991-05-01 ES ES91908598T patent/ES2124701T3/es not_active Expired - Lifetime
- 1991-05-01 DE DE69130576T patent/DE69130576T2/de not_active Expired - Fee Related
- 1991-05-01 JP JP91508106A patent/JPH05506234A/ja active Pending
- 1991-05-01 CA CA002082425A patent/CA2082425A1/en not_active Abandoned
- 1991-05-01 WO PCT/CA1991/000144 patent/WO1991016926A1/en not_active Ceased
- 1991-05-01 DK DK91908598T patent/DK0597838T3/da active
- 1991-05-01 AT AT91908598T patent/ATE173936T1/de not_active IP Right Cessation
- 1991-05-01 EP EP91908598A patent/EP0597838B1/de not_active Expired - Lifetime
- 1991-05-03 NZ NZ238042A patent/NZ238042A/xx unknown
- 1991-05-06 IE IE152791A patent/IE911527A1/en unknown
- 1991-05-06 CS CS911318A patent/CS131891A3/cs unknown
- 1991-05-06 MX MX025669A patent/MX172210B/es unknown
- 1991-05-07 CN CN91102899A patent/CN1056816A/zh active Pending
- 1991-05-07 YU YU79691A patent/YU79691A/sh unknown
- 1991-07-15 TW TW080105479A patent/TW221676B/zh active
1992
- 1992-11-06 NO NO92924271A patent/NO924271L/no unknown
1993
- 1993-04-01 HR HRP-796/91A patent/HRP930658A2/hr not_active Application Discontinuation

Also Published As

Publication number	Publication date
HU9203480D0 (en)	1993-01-28
FI925032A0 (fi)	1992-11-06
DE69130576D1 (de)	1999-01-14
IL97985A0 (en)	1992-06-21
ATE173936T1 (de)	1998-12-15
MX172210B (es)	1993-12-07
EP0597838A1 (de)	1994-05-25
CN1056816A (zh)	1991-12-11
ZA913214B (en)	1992-09-30
JPH05506234A (ja)	1993-09-16
TW221676B (de)	1994-03-11
HUT65493A (en)	1994-06-28
FI925032L (fi)	1992-11-06
CA2082425A1 (en)	1991-11-08
NO924271L (no)	1993-01-07
EP0597838B1 (de)	1998-12-02
FI925032A7 (fi)	1992-11-06
NO924271D0 (no)	1992-11-06
NZ238042A (en)	1993-12-23
HRP930658A2 (en)	1997-12-31
YU79691A (sh)	1994-06-10
DK0597838T3 (da)	1999-08-16
WO1991016926A1 (en)	1991-11-14
IE911527A1 (en)	1991-11-20
AU7777991A (en)	1991-11-27
ES2124701T3 (es)	1999-02-16
DE69130576T2 (de)	1999-07-29

Publication	Publication Date	Title
CA1329766C (en)	1994-05-24	T cell epitopes of the hepatitis b virus nucleocapsid protein
KR100290632B1 (ko)	2001-09-17	면역성이약한항원공액체와이를포함하는합성펩티드담체와백신
US5837250A (en)	1998-11-17	Adjuvant compositions
JP4031201B2 (ja)	2008-01-09	アレルギー治療用免疫原としてのペプチド組成物
CA2793087C (en)	2019-07-23	Peptides, conjugates and method for increasing immunogenicity of a vaccine
CS283991A3 (en)	1992-04-15	Vaccine
JPH09510975A (ja)	1997-11-04	アレルギー治療用合成ペプチドベース免疫原
WO1999050303A2 (en)	1999-10-07	Immune response modulator alpha-2 macroglobulin complex
CN104507496B (zh)	2018-08-03	包含与crm197载体蛋白偶联的hiv gp41肽的免疫原性化合物
CS131891A3 (en)	1992-02-19	Vaccine
US4919930A (en)	1990-04-24	Synthetic M proteins-streptococci type 5
Robinson et al.	1992	Palmitic acid conjugation of a protein antigen enhances major histocompatibility complex class II-restricted presentation to T cells
EP0166548A2 (de)	1986-01-02	Breitspekrum-Vakzin gegen Gonorrhea
US6290971B1 (en)	2001-09-18	Adjuvant compositions comprising a mineral salt and another immunostimulating compound
AU754988B2 (en)	2002-11-28	Immune response modulator alpha-2 macroglobulin complex
Wang	1993	B cell & T cell epitope orientation and adjuvant-free immunization in synthetic vaccine design
HUT71776A (en)	1996-01-29	Antibody conjugates with improved properties
EP0674907A2 (de)	1995-10-04	Antikörper-Trägerprotein-Konjugate, zur Verwendung bei der aktiven Immunotherapie